Moderna's gene therapy expansion picks up pace with $76M upfront Generation Bio collab

Moderna is keeping its foot on the gas in 2023 when it comes to expanding beyond mRNA. Having signed a gene-editing pact in January and scooped up a DNA manufacturer in February, this month sees the biotech giant hand over $76 million as part of a collaboration centered on nonviral genetic medicines with Generation Bio.